Search Results

Aronora, Inc., a clinical-stage biotech poised to revolutionize blood clot treatment and prevention, today announced it has closed an investment from NYBC Ventures, a venture fund established by New York Blood Center.

Check out five New York companies hiring biopharma professionals like you, including 2025 Best Places to Work winners.

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.

New York Blood Center Enterprises and Talaris Therapeutics, Inc. announced NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky.

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

Anteris Technologies Ltd announced a summation of the Company’s presentation at the New York Valves annual Conference held at the Jacob K. Javits Convention Center in New York City.

A new study published online and available in the February print edition of the journal Transfusion shows the mixed reality technology for use during blood donation created by Abbott and Blood Centers of America helps ease donors’ feelings of anxiety and boosts the likelihood they will return to give blood again.

Anteris Technologies Ltd, a structural heart company developing DurAVR™ THV, a new class of TAVR and the world’s only balloon-expandable, single-piece biomimetic aortic replacement valve shaped to mimic the native human valve, announced a summation of the Company’s presentation at the New York Valves annual Conference held at the Jacob K. Javits Convention Center in New York City.